REGENXBIO FY2025 EPS Forecast Reduced by Chardan Capital

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at Chardan Capital reduced their FY2025 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, May 14th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnology company will post earnings per share of ($3.25) for the year, down from their prior forecast of ($3.03). Chardan Capital has a "Buy" rating and a $52.00 price target on the stock. The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $89.01 million for the quarter, compared to analysts' expectations of $105.35 million.

Other equities research analysts have also issued research reports about the company. Morgan Stanley lifted their price target on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Royal Bank of Canada restated an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research note on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Stock Up 2.9%

RGNX opened at $8.89 on Monday. The business's fifty day simple moving average is $7.54 and its 200 day simple moving average is $7.97. REGENXBIO has a 52 week low of $5.04 and a 52 week high of $16.25. The stock has a market cap of $445.92 million, a PE ratio of -1.77 and a beta of 1.11.

Insider Buying and Selling at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the company's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the transaction, the director now directly owns 475,103 shares of the company's stock, valued at approximately $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.79% of the company's stock.

Institutional Trading of REGENXBIO

Several large investors have recently modified their holdings of RGNX. Assenagon Asset Management S.A. raised its position in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of REGENXBIO by 8.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company's stock valued at $1,273,000 after buying an additional 13,014 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO during the fourth quarter valued at approximately $1,062,000. Raymond James Financial Inc. bought a new position in shares of REGENXBIO during the fourth quarter valued at approximately $568,000. Finally, Teacher Retirement System of Texas lifted its stake in REGENXBIO by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after acquiring an additional 2,088 shares during the period. 88.08% of the stock is owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.